Press Release: EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Press Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding - WPRI News Channel 12 interview

Providence biotech company working to create coronavirus vaccine - Providence NBC 10 News interview

March 04, 2020 09:00 ET | Source: Generex Biotechnology Corporation MIRAMAR, Fla., March 04, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (https://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a contract with EpiVax (https://epivax.com/) to use their computational tools to predict epitopes that can be used to generate peptide vaccines against the nCOV-2019 corona virus ...

PROVIDENCE, R.I., Mar. 4, 2020 – EpiVax Inc., a Rhode Island company, announces a collaboration to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine with University of Georgia (UGA, Athens GA) vaccine expert Ted Ross (Director, Center for Vaccines and Immunology (CVI)).  The COVID-19 virus emerged in January 2020, impacting over 94,000 individuals, in China and ...

By Elizabeth Graham -February 21, 2020 2:35 am Find the full story here. Staying current on the frantic pace of the coronavirus outbreak means following reports by major news outlets for most people, but analysts at EpiVax Inc. are more interested in websites that share genetic sequences of the novel virus. Chinese health officials published the sequence in ...

EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

Providence, R.I., December 23, 2019 – EpiVax (“EpiVax, Inc.”) continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020. The Business Development team closed 15% more contracts over 2018 and acquired two new clients for ISPRI, the in silico immunogenicity screening and protein re-engineering interface, bringing the ...

Providence, R.I., December 17, 2019 EpiVax, Inc. (“EpiVax”), the home of “fearless science”, announces it will renew their company-wide commitment to “improving human health everywhere” in the new decade (2020). EpiVax has a greater than 20-year tradition of corporate giving to worthy charities, especially those that improve human (or animal) health. Each year a significant portion ...

Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction” in Scientific Reports, 06 Nov 2019, a Nature publication .  This research highlights ...

Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc. (“EpiVax”). Chugai, one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products, integrated the advanced ISPRI toolkit into their preclinical assessment pipeline after an extended head-to-head comparison with other in ...

Providence, R.I., May 28, 2019 – EpiVax, Inc. is celebrating the company’s 21st birthday in Providence by renewing its commitment to improving human health everywhere and highlighting the work of two not-for-profit organizations that have been partners with EpiVax for nearly all of those 21 years. Clínica Esperanza/Hope Clinic (CEHC) is located near EpiVax’s headquarters in ...

THIS ORIGINAL ARTICLE WAS PUBLISHED IN PR NEWSWIRE. LINK TO THE ORIGINAL ARTICLE CAN BE FOUND HERE. NEW YORK, March 25, 2019 /PRNewswire/ — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for an oral presentation, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, taking place on March ...

Making Epi-Resolutions for 2019: In 2019, EpiVax will strive to help improve human-to-human interactions, while supporting the right of every human to speak freely, to be healthy, to build diverse communities and to wage peace. We will also promote humane practices towards animals and work to protect and honor the Earth, our home. And, of course, ...